Abstract: 3-Phenoxyazetidines having the formula: ##STR1## wherein R is hydrogen, aminocarbonyl and trifluoromethyl having anorexigenic activity are disclosed.

Abstract: The resolution of racemic 4-amino-N-(1-cyclohexyl-3-pyrrolidinyl)-N-methylbenzamide into the optically active (+) and (-) isomers is disclosed.

Abstract: This invention provides a novel class of 2-iminoimidazolidines which include 4-substituted derivatives such as 4-(2-chloroethyl)-1-methyl-2-methylimino-3-phenyl imidazolidine fumarate: ##STR1## This illustrated 4-substituted 2-iminoimidazolidine compound exhibits cardiovascular hypotensive, hypoglycemic (glucose tolerance, and sugar cataract) and anti-inflammatory (pleural effusion) pharmacological activities in test animals.

Abstract: This invention provides a novel class of 2-iminoimidazolidines which include 4-substituted derivatives such as 4-(2-chloroethyl)-1-methyl-2-methylimino-3-phenyl imidazolidine fumarate: ##STR1## This illustrated 4-substituted 2-iminoimidazolidine compound exbibits cardiovascular hypotensive, hypoglycemic (glucose tolerance, and sugar cataract) and anti-inflammatory (pleural effusion) pharmacological activities in test animals.

Abstract: This invention provides a novel class of 2-iminoimidazolidines which include 4-substituted derivatives such as 4-(2-chloroethyl)-1-methyl-2-methylimino-3-phenyl imidazolidine fumarate: ##STR1## This illustrated 4-substituted 2-iminoimidazolidine compound exhibits cardiovascular hypotensive, hypoglycemic (glucose tolerance, and sugar cataract) and anti-inflammatory (pleural effusion) pharmacological activities in test animals.

Abstract: 1-Hydrocarbon-3,3-diphenyl-4-hydroxymethyl-2-pyrrolidinones and methods for making them from 4,5-dihydro-3,3-diphenyl-4-hydrocarbylaminomethylfuran-2(3H)ones are disclosed. Methods for making the 4,5-dihydro-3,3-diphenyl-4-hydrocarbylaminomethylfuran-2(3H)ones are also disclosed. The novel compounds are useful intermediates for the preparation of pharmacologically active 4-(4,4-disubstitutedpiperidinylmethyl)-3,3-diphenyl-2-pyrrolidinones.

Abstract: This invention provides a novel class of 2-iminoimidazolidines which include 4-substituted derivatives such as 4-(2-chloroethyl)-1-methyl-2-methylimino-3-phenyl imidazolidine fumarate: ##STR1## This illustrated 4-substituted 2-iminoimidazolidine compound exhibits cardiovascular hypotensive, hypoglycemic (glucose tolerance, and sugar cataract) and anti-inflammatory (pleural effusion) pharmacological activities in test animals.

Abstract: This invention provides a novel class of 2-iminoimidazolidines which include 4-substituted derivatives such as 4-(2-chloroethyl)-1-methyl-2-methylimino-3-phenyl imidazolidine fumarate: ##STR1## This illustrated 4-substituted 2-iminoimidazolidine compound exhibits cardiovascular hypotensive, hypoglycemic (glucose tolerance, and sugar cataract) and anti-inflammatory (pleural effusion) pharmacological activities in test animals.

Abstract: The resolution of racemic 4-amino-N-(1-cyclohexyl-3-pyrrolidinyl)-N-methylbenzamide into the optically active (+) and (-) isomers is disclosed.

Abstract: The resolution of racemic 4-amino-N-(1-cyclohexyl-3-pyrrolidinyl)-N-methylbenzamide into the optically active (+) and (-) isomers is disclosed.

Abstract: N-(1-Substituted-3-pyrrolidinyl)benzamides of the formula ##STR1## wherein R is cycloalkyl or phenyllower-alkyl; R.sup.1 is hydrogen or lower alkyl of 1 to 8 carbon atoms; R.sup.2 is acetamido, amino, methylamino, dimethylamino, benzyloxy, halogen, lower alkoxy, methylmercapto, nitro, cyano, hydroxy, sulfamoyl, bis(methylsulfonyl)amino, methylsulfonylamino, aminomethyl or acetylaminomethyl and can be the same or different; n is an integer from one to three inclusive with the proviso that when R.sup.2 is amino, nitro, halogen or lower alkoxy, n is greater than one, and pharmaceutically acceptable acid addition salts thereof are disclosed.

Abstract: This invention provides a novel class of 3-methyleneazetidines which include diphenylmethyl derivatives such as 1-isopropyl-3-diphenylmethyleneazetidine oxalate: ##STR1## This illustrated 3-methyleneazetidine compound is characterized by a combination of pharmacological properties which are indicative of utility as a mood elevating therapeutic agent for relieving the symptoms of depression in humans. The illustrated compound exhibits an ED.sub.50 (tetrabenazine-induced ptosis) of 2.18 mg/kg in mice.

Abstract: This invention provides a novel class of 2-iminoimidazolidines which include 4-substituted derivatives such as 4-(2-chloroethyl)-1-methyl-2-methylimino-3-phenyl imidazolidine fumarate: ##STR1## This illustrated 4-substituted 2-iminoimidazolidine compound exhibits cardiovascular hypotensive, hypoglycemic (glucose tolerance, and sugar cataract) and anti-inflammatory (pleural effusion) pharmacological activities in test animals.

Abstract: This invention provides an improved process for producing methylene-cycloamines as exemplified by 1-isopropyl-3-diphenylmethyleneacetidine: ##STR1## In accordance with the invention process, the above illustrated methyleneazetidine compound is synthesized by (1) reacting .alpha.,.alpha.-diphenyl-.alpha.-(1-isopropyl-3-azetidinyl) acetamide with bromine and alkali metal alkoxide under modified Hofmann Rearrangement conditions to form a carbamate intermediate, and (2) heating the carbamate intermediate in an acidic medium to yield the 1-isopropyl-3-diphenylmethyleneazetidine product.This illustrated 3-methyleneazetidine compound is characterized by a combination of pharmacological properties which are indicative of utility as a mood elevating therapeutic agent for relieving the symptoms of depression in humans.

Abstract: N-Lower-alkyl 3-phenoxy-1-azetidinecarboxamides having the formula: ##STR1## wherein R is alkyl and R.sup.1 is hydrogen, aminocarbonyl and trifluoromethyl having central nervous system activity particularly anti-convulsant activity, are disclosed.

Abstract: N-(4-Pyrazolidinyl)benzamides having the formula ##STR1## and their amino precursors are disclosed wherein R is lower alkyl, lower cycloalkyl or phenyllower-alkyl; R.sup.1 is lower alkyl, lower cycloalkyl, or phenyllower-alkyl; R.sup.2 is hydrogen, lower alkyl or phenyl; R.sup.3 is hydroxy, cyano, nitro, amino, fluoro, chloro, bromo, trifluoromethyl, lower alkyl, lower alkoxy, sulfamoyl or actamido, R.sup.3 can be the same radical or different radicals; n is an integer from zero to three inclusive, and pharmaceutically acceptable acid addition salts thereof. The compounds have anti-emetic and gastric emptying properties.

Abstract: 1-Hydrocarbon-3,3-diphenyl-4-hydroxymethyl-2-pyrrolidinones and methods for making them from 4,5-dihydro-3,3-diphenyl-4-hydrocarbylaminomethylfuran-2(3H)ones are disclosed. Methods for making the 4,5-dihydro-3,3-diphenyl-4-hydrocarbylaminomethylfuran-2(3H)ones are also disclosed. The novel compounds are useful intermediates for the preparation of pharmacologically active 4-(4,4-disubstitutedpiperidinylmethyl)-3,3-diphenyl-2-pyrrolidinones.

Abstract: Oxanilic acid derivatives having the formula: ##STR1## are disclosed wherein R is lower-alkyl, cycloalkyl, phenylalkyl or phenyl; R.sup.1 is hydrogen, lower-alkyl or phenyl; R.sup.2 is hydrogen, lower-alkyl, or lower-alkoxy; R.sup.3 is hydrogen, fluoro, chloro or bromo; X is oxygen or sulfur; and M is hydrogen, lower-alkyl or a physiologically acceptable cation. The compounds are useful for ameliorating and controlling symptoms associated with asthma.

Abstract: .alpha.-(1-R-3-Azetidinyl)-.alpha.-phenyl-.alpha.-substituted-acetamides and -acetonitriles represented by the following formula: ##STR1## wherein R represents hydrogen, lower alkyl, lower cycloalkyl or phenyllower alkyl, R.sup.1 represents phenyl or 2-pyridyl, and Y is carbamoyl or cyano having antiarrhythmic activity are disclosed. Pharmaceutically acceptable acid addition salts of the free bases and quaternary salts are included as part of the invention.

Abstract: Novel amides of norfenfluramine having the formula ##STR1## wherein R is selected from the group consisting of alkyl and alkenyl radicals having 12 to 22 carbon atoms and compositions and methods for combating atherosclerosis and hypercholesteremia, with beneficial side effects useful for combating obesity in atherosclerotic subjects are disclosed. The compounds lower lipid values and simultaneously inhibit appetite and reduce weight gain from ingested food with minimal side effects.